Usefulness of serum anti-p53 antibody assay for lung cancer diagnosis

Yongjung Park, Yoonjung Kim, Jong Han Lee, Eun Young Lee, Hyon Suk Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Context.-Some tumor markers, including carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA 21-1), are used for the detection of lung cancer; however, their use is limited because of low sensitivities and high false-positive rates. Objectives.-To investigate the usefulness of an anti-p53 assay in detecting lung cancer and to compare the anti-p53 to CEA and CYFRA 21-1 tumor markers. Design.-Serum samples were collected from 82 patients with lung cancer. Serawere also collected from79patients with or without benign pulmonary disease for the control group. All 161 specimens were assayed for CEA, CYFRA 21-1, and antip53. The diagnostic performances of these markers were compared using receiver operating characteristic analysis. Results.-The receiver operating characteristic area under the curve values of CYFRA 21-1, CEA, and anti-p53 for discriminating lung cancers from benign or healthy conditions were 0.79, 0.81, and 0.79, respectively. Area under the curve for the 3 markers in combination was 0.90. The sensitivities of those markers for lung cancer detection were respectively 39.0%, 53.7%, and 34.1% at 94.9% specificity, and the cutoff levels at those sensitivities and specificities were 4.5 ng/mL for CYFRA 21-1, 5.4 ng/mL for CEA, and 2.7 U/mL for anti-p53. We found 79.3% positive results for patients with lung cancer by any of the 3 markers, and 12.2% were positive only for anti-p53. All patients without cancer had negative results for 2 or all 3 markers. Conclusions.-Anti-p53 combined with other conventional markers is helpful in increasing the sensitivity and specificity for detecting lung cancer.

Original languageEnglish
Pages (from-to)1570-1575
Number of pages6
JournalArchives of Pathology and Laboratory Medicine
Volume135
Issue number12
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

Anti-Idiotypic Antibodies
Lung Neoplasms
Carcinoembryonic Antigen
Serum
Tumor Biomarkers
ROC Curve
Area Under Curve
Keratin-19
Sensitivity and Specificity
Lung Diseases
antigen CYFRA21.1
Control Groups
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Park, Yongjung ; Kim, Yoonjung ; Lee, Jong Han ; Lee, Eun Young ; Kim, Hyon Suk. / Usefulness of serum anti-p53 antibody assay for lung cancer diagnosis. In: Archives of Pathology and Laboratory Medicine. 2011 ; Vol. 135, No. 12. pp. 1570-1575.
@article{14e3cd07cc334317a7bde41f8f870cc3,
title = "Usefulness of serum anti-p53 antibody assay for lung cancer diagnosis",
abstract = "Context.-Some tumor markers, including carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA 21-1), are used for the detection of lung cancer; however, their use is limited because of low sensitivities and high false-positive rates. Objectives.-To investigate the usefulness of an anti-p53 assay in detecting lung cancer and to compare the anti-p53 to CEA and CYFRA 21-1 tumor markers. Design.-Serum samples were collected from 82 patients with lung cancer. Serawere also collected from79patients with or without benign pulmonary disease for the control group. All 161 specimens were assayed for CEA, CYFRA 21-1, and antip53. The diagnostic performances of these markers were compared using receiver operating characteristic analysis. Results.-The receiver operating characteristic area under the curve values of CYFRA 21-1, CEA, and anti-p53 for discriminating lung cancers from benign or healthy conditions were 0.79, 0.81, and 0.79, respectively. Area under the curve for the 3 markers in combination was 0.90. The sensitivities of those markers for lung cancer detection were respectively 39.0{\%}, 53.7{\%}, and 34.1{\%} at 94.9{\%} specificity, and the cutoff levels at those sensitivities and specificities were 4.5 ng/mL for CYFRA 21-1, 5.4 ng/mL for CEA, and 2.7 U/mL for anti-p53. We found 79.3{\%} positive results for patients with lung cancer by any of the 3 markers, and 12.2{\%} were positive only for anti-p53. All patients without cancer had negative results for 2 or all 3 markers. Conclusions.-Anti-p53 combined with other conventional markers is helpful in increasing the sensitivity and specificity for detecting lung cancer.",
author = "Yongjung Park and Yoonjung Kim and Lee, {Jong Han} and Lee, {Eun Young} and Kim, {Hyon Suk}",
year = "2011",
month = "12",
day = "1",
doi = "10.5858/arpa.2010-0717-OA",
language = "English",
volume = "135",
pages = "1570--1575",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "12",

}

Usefulness of serum anti-p53 antibody assay for lung cancer diagnosis. / Park, Yongjung; Kim, Yoonjung; Lee, Jong Han; Lee, Eun Young; Kim, Hyon Suk.

In: Archives of Pathology and Laboratory Medicine, Vol. 135, No. 12, 01.12.2011, p. 1570-1575.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Usefulness of serum anti-p53 antibody assay for lung cancer diagnosis

AU - Park, Yongjung

AU - Kim, Yoonjung

AU - Lee, Jong Han

AU - Lee, Eun Young

AU - Kim, Hyon Suk

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Context.-Some tumor markers, including carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA 21-1), are used for the detection of lung cancer; however, their use is limited because of low sensitivities and high false-positive rates. Objectives.-To investigate the usefulness of an anti-p53 assay in detecting lung cancer and to compare the anti-p53 to CEA and CYFRA 21-1 tumor markers. Design.-Serum samples were collected from 82 patients with lung cancer. Serawere also collected from79patients with or without benign pulmonary disease for the control group. All 161 specimens were assayed for CEA, CYFRA 21-1, and antip53. The diagnostic performances of these markers were compared using receiver operating characteristic analysis. Results.-The receiver operating characteristic area under the curve values of CYFRA 21-1, CEA, and anti-p53 for discriminating lung cancers from benign or healthy conditions were 0.79, 0.81, and 0.79, respectively. Area under the curve for the 3 markers in combination was 0.90. The sensitivities of those markers for lung cancer detection were respectively 39.0%, 53.7%, and 34.1% at 94.9% specificity, and the cutoff levels at those sensitivities and specificities were 4.5 ng/mL for CYFRA 21-1, 5.4 ng/mL for CEA, and 2.7 U/mL for anti-p53. We found 79.3% positive results for patients with lung cancer by any of the 3 markers, and 12.2% were positive only for anti-p53. All patients without cancer had negative results for 2 or all 3 markers. Conclusions.-Anti-p53 combined with other conventional markers is helpful in increasing the sensitivity and specificity for detecting lung cancer.

AB - Context.-Some tumor markers, including carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA 21-1), are used for the detection of lung cancer; however, their use is limited because of low sensitivities and high false-positive rates. Objectives.-To investigate the usefulness of an anti-p53 assay in detecting lung cancer and to compare the anti-p53 to CEA and CYFRA 21-1 tumor markers. Design.-Serum samples were collected from 82 patients with lung cancer. Serawere also collected from79patients with or without benign pulmonary disease for the control group. All 161 specimens were assayed for CEA, CYFRA 21-1, and antip53. The diagnostic performances of these markers were compared using receiver operating characteristic analysis. Results.-The receiver operating characteristic area under the curve values of CYFRA 21-1, CEA, and anti-p53 for discriminating lung cancers from benign or healthy conditions were 0.79, 0.81, and 0.79, respectively. Area under the curve for the 3 markers in combination was 0.90. The sensitivities of those markers for lung cancer detection were respectively 39.0%, 53.7%, and 34.1% at 94.9% specificity, and the cutoff levels at those sensitivities and specificities were 4.5 ng/mL for CYFRA 21-1, 5.4 ng/mL for CEA, and 2.7 U/mL for anti-p53. We found 79.3% positive results for patients with lung cancer by any of the 3 markers, and 12.2% were positive only for anti-p53. All patients without cancer had negative results for 2 or all 3 markers. Conclusions.-Anti-p53 combined with other conventional markers is helpful in increasing the sensitivity and specificity for detecting lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=82655181367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82655181367&partnerID=8YFLogxK

U2 - 10.5858/arpa.2010-0717-OA

DO - 10.5858/arpa.2010-0717-OA

M3 - Article

C2 - 22129186

AN - SCOPUS:82655181367

VL - 135

SP - 1570

EP - 1575

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 12

ER -